NICE technology appraisal guidance
Issued: September 2012
TA264

Alteplase for treating acute ischaemic stroke (review of technology appraisal guidance 122)

This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/ta264

1 Guidance

This guidance replaces NICE technology appraisal guidance 122 (published in June 2007). For details see About this guidance.

1.1 Alteplase is recommended within its marketing authorisation for treating acute ischaemic stroke in adults if:

  • treatment is started as early as possible within 4.5 hours of onset of stroke symptoms, and

  • intracranial haemorrhage has been excluded by appropriate imaging techniques.